NECTIN4 and neoplasm: Similarly, TAC-003 enables systemic delivery of TRL9 by targeting tumor-expressing nectin-4 to facilitate tumor-homing TRL9 activation of immune cells.187 As such, approaches for systemic delivery of TRL9 agonists may overcome challenges associated with intratumoral injection and reinvigorate antitumor immunosurveillance.